You announced that you would acquire a sequence which is described as a quote platform for clinical weight management for $132 million. They prescribe a GLP one drugs, basically a Zempic. These are these drugs semi glue, glue tied something like that. And they are, they make you not hungry essentially.
WeightWatchers recently announced a $132 million deal to acquire telehealth company Sequence and enter the prescription drug space (think: GLP-1 drugs like Wegovy and Ozempic). It begs the question: why is a company built on personal accountability facilitating medical interventions? We ask our guest, WeightWatchers CEO Sima Sistani. Before and after the interview, Nayeema and Kara discuss their own experiences with diet fads and whether drugs like Wegovy and Ozempic will help America deal with the obesity epidemic or simply avoid tackling underlying issues like food supply, corporate greed and light regulation.
Questions? Comments? Email us at on@voxmedia.com or find us on Twitter @karaswisher and @nayeema
Learn more about your ad choices. Visit podcastchoices.com/adchoices